Olverembatinib Combos May Be ‘Promising’ in Ph+ Acute Lymphoblastic Leukemia

Commentary
Video

Combining olverembatinib with blinatumomab appears to produce high complete molecular remission rates in patients with newly diagnosed, Philadelphia chromosome–positive acute lymphoblastic leukemia, says Elias Jabbour, MD.

Olverembatinib (HQP1351) in combination with blinatumomab (Blincyto) may become a new standard of care for patients with acute lymphoblastic leukemia (ALL), although additional data and longer follow-up are necessary to confirm the combination’s efficacy, Elias Jabbour, MD, said in an interview with CancerNetwork® during the 2023 American Society of Hematologic (ASH) Annual Meeting and Exposition.

Jabbour, a professor of Medicine in the Department of Leukemia and Division of Cancer Medicine at The University of Texas, MD Anderson Cancer Center, discussed findings from an abstract presented at ASH that highlighted the activity of olverembatinib plus blinatumomab in a small population of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia. Although Jabbour stated that he currently administers olverembatinib monotherapy to treat patients at his practice, he said that the blinatumomab/olverembatinib combination appears to be a “promising” option that may warrant consideration as a therapy in the future.

According to data from the abstract, all patients (100%; n = 13/13) who received a single cycle of blinatumomab plus olverembatinib achieved a complete remission after a median follow-up of 7 months. Additionally, investigators highlighted a complete molecular remission rate of 72.7% after 1 cycle of treatment and 90.1% after 2 cycles.

Transcript:

Olverembatinib is a very potent Tyrosine kinase inhibitor in the third generation that has shown good efficacy. There are data on the combination of vincristine plus olverembatinib, and blinatumomab [plus olverembatinib], as well. [There were] quite good responses. Of course, we need longer follow up to see if this will be a new standard of care; we do not know yet, but that is something to keep an eye on. Blinatumomab/olverembatinib is quite promising, and that is to be explored down the road.

In Philadelphia [chromosome–positive ALL], at ASH, there were data on combining olverembatinib with blinatumomab or olverembatinib with low-dose chemotherapy. All have shown very good [complete molecular remission] rates, of upward to 60% to 70%. The future [plan] is to combine olverembatinib with blinatumomab.

Reference

Zhang T, Zhu K, Zihong C, Lin R, Liu Q, Zhou H. Frontline combination of 3rd generation TKI olverembatinib and blinatumomab for Ph+/Ph-like ALL patients. Blood. 2023;142(suppl 1):1504. doi:10.1182/blood-2023-186139

Recent Videos
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content